Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 301, Issue 3, 2011, Pages

  Lund, Amie K ^a   Lucero, Jo Ann ^a   Herbert, Lindsay ^a   Liu, Yushi ^b   Naik, Jay S ^a  

^a Department of Environmental and Cardiopulmonary Toxicology ^*  (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Echocardiograph; Human immunodeficiency virus associated pulmonary arterial hypertension; Microarray; Right ventricular systolic pressure

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HUMAN IMMUNODEFICIENCY VIRUS; JUGULAR VEIN; LUNG BLOOD VESSEL; MALE; MICROARRAY ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RIGHT VENTRICULAR SYSTOLIC PRESSURE; TRANSGENIC RAT; VEIN CATHETERIZATION;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HIV INFECTIONS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; PULMONARY ARTERY; RATS; RATS, INBRED F344; RATS, TRANSGENIC; VENTRICULAR FUNCTION, RIGHT;

EID: 80052367060     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00045.2011     Document Type: Article

References (62)

1. Amabile N, Heiss C, Real WM, Minasi P, McGlothlin D, Rame EJ, Grossman W, De Marco T, Yeghiazarians Y. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med 177: 1268-1275, 2008.
2. Anonymous. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. J Am Coll Cardiol 43: 1S-90S, 2004.
3. Archer SL, Souil E, Dinh-Xuan AT, Shremmer B, Mercier JC, El Yaagoubi A, Nguyen-Huu L, Reeve HL, Hampl V. Molecular identification of the role of voltage-gated K channels, Kv1.5 and Kv21, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 101: 2319-2330, 1998.
4. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 32: 945-951, 2011.
5. Benisty JI. Pulmonary hypertension. Circulation 106: E192-E194, 2002.
6. Caldwell RL, Gadipatti R, Lane KB, Shepherd VL. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J Leukoc Biol 79: 192-201, 2006.
7. Christou H, Yoshida A, Arthur V, Morita T, Kourembanas S. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 18: 768-776, 1998.
8. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28: 434-442, 1997.
9. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155: 411-419, 1999.
10. Degano B, Guillaume M, Savale L, Montani D, Jais X, Yaici A, Pavec JL, Humbert M, Simonneau G, Sitbon O. HIV-associated pulmonary hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 24: 67-75, 2010.
11. Ehrenreich H, Rieckmann P, Sinowatz F, Weih KA, Arthur LO, Goebel FD, Burd PR, Coligan JE, Clouse KA. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 150: 4601-4609, 1993.
12. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34: 1219-1263, 2009.
13. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, Eddahibi S. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98: 1323-1330, 2006.
14. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316, 1999.
15. Hsue PY, Farah HH, Palav S, Ahmed SY, Schnell A, Ellman AB, Huang L, Dollard SC, Martin JN. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 22: 825-383, 2008.
16. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 92: 1-20, 2001.
17. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 45: 173-202, 2002.
18. Kanmogne GD, Primeaux C, Grammas P. Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. Biochem Biophys Res Commun 333: 1107-1115, 2005.
19. Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 28: 202-208, 1996.
20. Lund AK, Lucero J, Lucas S, Madden MC, McDonald JD, Seagrave JC, Knuckles TL, Campen MJ. Vehicular emissions induce vascular MMP-9 expression and activity associated with endothelin-1-mediated pathways. Arterioscler Thromb Vasc Biol 29: 511-517, 2009.
21. Madeddu P, Emanueli C, El-Dahr S. Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol 3: 208-221, 2007.
22. Marecki JC, Cool CD, Parr JE, Beckey VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, Voelkel NF, Flores SC. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-Nef-infected macaques. Am J Respir Crit Care Med 174: 437-445, 2006.
23. McMurtry IF, Abe K, Ota H, Fagan KA, Oka M. Rho kinase-mediated vasoconstriction in pulmonary hypertension. Adv Exp Med Biol 661: 299-308, 2010.
24. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 188: 1133-1141, 2000.
25. Mette S, Palevsky H, Pietra G. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 145: 1196-1200, 1992.
26. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hop-kins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL. Dichlo-roacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105: 244-250, 2002.
27. Morrell NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-1 and bone morphogenetic proteins. Circulation 104: 790-795, 2001.
28. Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, Phillips JA 3rd, Knowles JA, Janssen B, Eickelberg O, Eddahibi S, Herve P, Nichols WC, Elliott G. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 345: 319-324, 2001.
29. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Hervé P, Barst RJ, Simonneau G. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 167: 1433-1439, 2003.
30. Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, Hirschel B, Lüthy R. HIV-associated primary pulmonary hypertension. A case control study Swiss HIV Cohort Study. Am J Respir Crit Care Med 155: 990-995, 1997.
31. Opravil M, Sereni D. Natural history of HIV-associated pulmonary hypertension: trends in HAART era. AIDS 22: 35-40, 2008.
32. Orte C, Polak JM, Haworth SG, Haworth SG, Yacoub MH, Morrell NW. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary pulmonary hypertension. J Pathol 192: 379-384, 2000.
33. Ozaki M, Kawashima S, Yamashita T, Ohashi Y, Rikitake Y, Inoue N, Hirata KI, Hayashi Y, Itoh H, Yokoyama M. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension 37: 322-327, 2001.
34. Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, Raffestin B, Frelin C. Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 275: H1948-H1956, 1998.
35. Pellicelli AM, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related pulmonary hypertension. Ann NY Acad Sci 946: 82-94, 2001.
36. Perros F, Montani D, Dorfmüller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E, Mussot S, Mercier O, Hervé P, Emilie D, Eddahibi S, Simonneau G, Souza R, Humbert M. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 81-88, 2008.
37. Petrosillo N, Chinello P, Cicalini S. Pulmonary hypertension in individuals with HIV infection. AIDS 20: 2128-2129, 2006.
38. Pozeg ZI, Michelakis ED, McMurtry MS, Thébaud B, Wu XC, Dyck JRB, Hashimoto K, Wang S, Moudgil R, Harry G, Sultanian R, Koshal A, Archer SL. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 107: 2037-2044, 2003.
39. Prabha M, Jin HF, Tian Y, Tang CS, Du JB. Mechanisms responsible for pulmonary hypertension. Chin Med J (Engl) 121: 2604-2609, 2008.
40. Pruznak AM, Hong-Brown L, Lantry R, She P, Frost RA, Vary TC, Lang CH. Skeletal and cardiac myopathy in HIV-1 transgenic rats. Am J Physiol Endocrinol Metab 295: E964-E973, 2008.
41. Rahim MM, Chrobak P, Hu C, Hanna Z, Jolicoeur P. Adult AIDS-like disease in a novel inducible human immunodeficiency virus type 1 Nef transgenic mouse model: CD4 T-cell activation is Nef dependent and can occur in the absence of lymphopenia. J Virol 83: 11830-11846, 2009.
42. Reid W, Sadowska M, Denaro F, Rao S, Foulke J, Hayes N, Jones O, Doodnauth D, Davis H, Sill A, O'Driscoll P, Huso D, Fous T, Lewis G, Hill M, Kamin-Lewis R, Wei C, Ray P, Gallo RC. An HIV-1 transgenic rat that develops HIV-related pathology an immunologic dysfunction. Proc Natl Acad Sci USA 98: 9271-9276, 2001.
43. Reigstad LF, Varhaug JE, Lillehaug JR. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 272: 5723-5741, 2005.
44. Resta TC, Chicoine LG, Omdahl JL, Walker BR. Maintained upregulation of pulmonary eNOS gene and protein expression during recovery from chronic hypoxia. Am J Physiol Heart Circ Physiol 276: H699-H708, 1999.
45. Rich S, Brundage B. Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment. J Am Coll Cardiol 14: 545-550, 1989.
46. Rubin LJ. Pathology and pathophysiology of primary pulmonary hypertension. Am J Cardiol 75: 51A-54A, 1995.
47. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissman N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821, 2005.
48. Schultz K, Fanburg BL, Beasley D. Hypoxia and hypoxia-inducible factor-1 promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 290: H2528-H2534, 2006.
49. Shimoda LA, Manalo DJ, Sham JS, Semenza GL, Sylvester JT. Partial HIF-1 deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 281: L202-L208, 2001.
50. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S43-S54, 2009.
51. Sitbond O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, Gressin V, Clerson P, Sereni D, Simonneau G. Prevalence of HIV-related pulmonary hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 177: 108-113, 2008.
52. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 100: 1268-1271, 1991.
53. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99: 675-691, 2006.
54. Tavares de Lima W, Kwasniewski FH, Sirois P, Janear S. Studies on the mechanism of PAF-induced vasopermeability in rat lungs. Prostaglandins Leukocyte Essent Fatty Acids 52: 245-249, 1995.
55. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliot GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-family. J Med Genet 37: 741-745, 2000.
56. Tuder RM, Flook BE, Voelkel NF. Increased expression of VEGF and VEGF receptors KDR/Flk and Flt in lungs exposed to acute or chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95: 1798-1807, 1995.
57. Voelkel NF, Flores S, Petrosillo N. PVRI Task Force Annual Reports-2008: Pulmonary Hypertension Associated With HIV Task Force. Ann Rep PVRI Task Forces 1: 51-53, 2009.
58. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 8: 2129-2138, 1995.
59. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JSK, Wiener CM, Sylvester JT, Semeza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1.JClinInvest 103:691-696,1999.
60. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin LJ. Attenuated K channel gene transcription in primary pulmonary hypertension. Lancet 351: 726-727, 1998.
61. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96: 442-450, 2005.
62. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HSK, Vogel SM, Brovkovych V, Yuan JXJ, Wharton J, Malik AB. Persistent Enos activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 119: 2009-2018, 2009.